 IRVINE, Calif.--BUSINESS WIRE--Axonics Modulation Technologies, Inc. Nasdaq: AXNX, a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation SNM devices for the treatment of urinary and bowel dysfunction, has received PMA supplement approval from the U.S. Food Drug Administration FDA for its third-generation implantable neurostimulator INS. This marks the sixth FDA approval Axonics has received for a significant product innov 